Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Abstract Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinic...

Full description

Bibliographic Details
Main Authors: Ivan Foeldvari, Tamàs Constantin, Jelena Vojinović, Gerd Horneff, Vyacheslav Chasnyk, Joke Dehoorne, Violeta Panaviene, Gordana Sušić, Valda Stanevicha, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Irina Nikishina, Brigitte Bader-Meunier, Luciana Breda, Pavla Doležalová, Chantal Job-Deslandre, Ingrida Rumba-Rozenfelde, Nico Wulffraat, Ronald D. Pedersen, Jack F. Bukowski, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO)
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Arthritis Research & Therapy
Subjects:
Etanercept
Juvenile idiopathic arthritis
Enthesitis-related arthritis
Extended oligoarticular juvenile idiopathic arthritis (eoJIA)
Enthesitis-related arthritis (ERA)
Psoriatic arthritis (PsA)
Online Access:http://link.springer.com/article/10.1186/s13075-019-1916-9

Internet

http://link.springer.com/article/10.1186/s13075-019-1916-9

Similar Items